{'fraction_non_alphanumeric': 0.02365491651205937, 'fraction_numerical': 0.00510204081632653, 'mean_word_length': 5.719626168224299, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Smoothened is a therapeutic target for reducing glutamate toxicity in ischemic stroke

Description Activation of SHH pathway contributes to glutamate toxicity, and inhibition of SMO reduces ischemic brain damage in mice and monkeys. A smooth-ened approach for ischemia One of the consequences of brain ischemia is the release of glutamate from the intracellular milieu onto the extracellular space where it contributes to neuronal damage. To understand the mechanisms mediating glutamate release and uptake in ischemic condition, Wang et al. used in vivo models of brain ischemia in rodents and nonhuman primates. The authors found that the protein Smoothened (SMO) contributes to extracellular glutamate accumulation by decreasing the membrane expression of the glutamate transporter GLT-1. Inhibiting SMO using an FDA-approved drug was therapeutic in rodent and monkey models, suggesting that targeting SMO could be effective for reducing the deleterious consequences of brain ischemia. Extracellular glutamate contributes to brain damage in ischemia. Under physiological conditions, glutamate transporters are responsible for regulating its intracellular/extracellular concentrations in the brain. However, how the extracellular glutamate is regulated in ischemia remains unclear. Here, we showed that the sonic hedgehog (SHH)–Smoothened (SMO)–GLT-1 pathway controlled extracellular glutamate and blocking SMO reduced ischemic brain damage in rodents. SHH was quickly released in a rodent model of ischemia, and activation of its pathway was associated with neuronal damage. Inhibiting SMO, the mediator of SHH signaling, maintained GLT-1 membrane expression, lowered extracellular glutamate, reduced infarct volume, and improved neurological functions in mice. Mechanistically, SHH suppressed GLT-1 membrane expression via PKCα phosphorylation of serine-562 on GLT-1. Last, administration of NVP-LDE225, an FDA-approved SMO antagonist used for cancer treatment in clinic, had protective effects in mice and cynomolgus monkeys subjected to ischemia. Together, these results suggest that SMO could be targeted for treating glutamate toxicity in ischemia.